EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Non-small-cell lung cancer (NSCLC) is a major health concern.
• Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) show efficacy in NSCLC treatment.
• The impact of EGFR-TKIs on the tumor immune microenvironment remains largely unknown.

Purpose of the Study:

• To investigate the relationship between EGFR mutation status and PD-L1 expression in NSCLC.
• To determine the effect of EGFR-TKIs on PD-L1 expression in EGFR-mutant NSCLC.
• To elucidate the underlying mechanism of EGFR-TKI action on PD-L1.

Main Methods:

• Comparative analysis of PD-L1 expression in NSCLC with wild-type versus mutant EGFR.
• In vitro and in vivo experiments using EGFR-TKI gefitinib on EGFR-mutant NSCLC models.
• Assessment of NF-κB signaling pathway activity.

Main Results:

• NSCLCs with EGFR mutations exhibit significantly higher PD-L1 expression compared to those with wild-type EGFR.
• EGFR activation is positively correlated with elevated PD-L1 levels.
• Gefitinib treatment effectively reduces PD-L1 expression in EGFR-mutant NSCLC by inhibiting the NF-κB pathway.

Conclusions:

• EGFR mutation status influences the tumor immune microenvironment by upregulating PD-L1.
• EGFR-TKIs possess a novel anti-tumor mechanism involving PD-L1 downregulation.
• Combining EGFR-targeted therapy with immunotherapy presents a promising strategy for EGFR-mutant NSCLC patients.